Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. insiders are currently net buyers of BDTX stock, showing bullish sentiment over the past 90 days. Executives have purchased $105.5M while selling $29.1M, resulting in a positive net flow of $76.4M. This buying activity represents 78% of total transaction volume.

Black Diamond Therapeutics, Inc. has 29 active insiders who have filed SEC Form 4 transactions in the past 90 days. Bradley J. Bolzon Phd (Executive) leads with 182 transactions totaling $28.7M. Rajeev M. Shah (Executive) follows with 12 transactions worth $27.6M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Black Diamond Therapeutics, Inc.'s current score of 78/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $105.5M in purchases versus $29.1M in sales.

The most recent insider transaction occurred on Mar 20, 2026, when Raman Prakash (Executive) acquired 6,105 shares at $2.15 per share for $13.1K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, BDTX insider trading sentiment is currently bullish with an Alignment Score of 78/100. The net insider flow of $76.4M reflects accumulation, with 78% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Black Diamond Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At BDTX, we track all Form 4 filings—currently showing 546 transactions from 29 insiders over 90 days.

A 10b5-1 plan allows Black Diamond Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At BDTX, approximately 2% of recent transactions are 10b5-1 trades. The remaining 98% are discretionary trades, which may carry more informational value.

You can monitor Black Diamond Therapeutics, Inc. (BDTX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 29 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Black Diamond Therapeutics, Inc.'s current score of 78/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $105.5M in purchases versus $29.1M in sales over 90 days, resulting in a net flow of $76.4M.

SEC Form 4 filings are mandatory reports that Black Diamond Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At BDTX, the most common type is "A" with 43 occurrences. The most recent Form 4 was filed on Mar 20, 2026 by Raman Prakash.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Black Diamond Therapeutics, Inc., approximately 2% of recent transactions are executed under 10b5-1 plans, while 98% appear to be discretionary trades. The low percentage means most insider activity at BDTX represents discretionary decisions with more informational value.